SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001493152-24-051958 from ZyVersa Therapeutics, Inc. (ZVSA)

ZyVersa Therapeutics, Inc.
Date: Dec. 26, 2024 · CIK: 0001859007 · Accession: 0001493152-24-051958

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-283993

Date
December 26, 2024
Author
ZYVERSA
Form
CORRESP
Company
ZyVersa Therapeutics, Inc.

Letter

ZyVersa Therapeutics, Inc.

N. Commerce Parkway, Suite 208

Weston, Florida 33326

(754) 231-1688

December 23, 2024

VIA EDGAR SUBMISSION

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: ZyVersa Therapeutics, Inc. (the “Company”)

Registration Statement on Form S-3 (File No. 333-283993) (the “Registration Statement”)

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, the Company hereby requests that the U.S. Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement to become effective on Friday, December 26, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable, unless the Company notifies you otherwise prior to such time.

If you have any questions regarding this request, please contact our outside counsel, Faith Charles of Thompson Hine LLP, by telephone at (212) 908-3905 or via email at Faith.Charles@ThompsonHine.com. Please also call Faith Charles as soon as the Company’s Registration Statement has been declared effective. Thank you for your attention to this matter.

Sincerely,
ZYVERSA
THERAPEUTICS, INC.

Show Raw Text
CORRESP
1
filename1.htm

ZyVersa
Therapeutics, Inc.

2200
N. Commerce Parkway, Suite 208

Weston,
Florida 33326

(754)
231-1688

December
23, 2024

VIA
EDGAR SUBMISSION

U.S.
Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: ZyVersa Therapeutics, Inc. (the “Company”)

                                                                                Registration Statement on Form S-3 (File No. 333-283993) (the “Registration Statement”)

Ladies
and Gentlemen:

Pursuant
to Rule 461 of the Securities Act of 1933, as amended, the Company hereby requests that the U.S. Securities and Exchange Commission
take appropriate action to cause the above-referenced Registration Statement to become effective on Friday, December 26, 2024, at 4:30
p.m., Eastern Time, or as soon thereafter as is practicable, unless the Company notifies you otherwise prior to such time.

If
you have any questions regarding this request, please contact our outside counsel, Faith Charles of Thompson Hine LLP, by telephone at
(212) 908-3905 or via email at Faith.Charles@ThompsonHine.com. Please also call Faith Charles as soon as the Company’s Registration
Statement has been declared effective. Thank you for your attention to this matter.

  Sincerely,

  ZYVERSA
  THERAPEUTICS, INC.

  By:
  /s/
  Stephen C. Glover

  Name:
  Stephen
  C. Glover

  Title:
  Chief
  Executive Officer

cc:
Faith Charles, Thompson Hine LLP